Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA

REFERENCES

• Fliser D, Haller H. Nephropathie bei diabetes mellitus type 2 (Nephropathy in type 2 DM). Der Internist 2000;41:1363–1373.
   PubMedGoogle Scholar
• Foley RN, Collins AJ. End-stage renal disease in the United States: An update from the United States Renal Data System. J Am Soc Nephrol 2007;18:2644–2648.
   PubMed Web of Science ®Google Scholar
• Dor A, Pauly MV, Eichleay MA, Held PJ. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007;7:73–111.
   PubMedGoogle Scholar
• Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006;30 (12):895–897.
   PubMed Web of Science ®Google Scholar
• Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patients numbers, treatment modalities and associated trends. Nephrology, Dialysis, Transplantation 2005;20:2587–2593;
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476–481.
   PubMed Web of Science ®Google Scholar
• US Renal Data System: Economic costs of ESRD. Am J Kidney Dis 2000;36(suppl 2): S163–S176.
   Google Scholar
• Tomson CR. Recent advances: Nephrology. BMJ 2000;320:98–101.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM. Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care 2003;26(3):683–687.
   PubMed Web of Science ®Google Scholar
• Weinstein M, Stason WB. On the foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716–721.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.
   Google Scholar
• Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3(2):95–104.
   PubMed Web of Science ®Google Scholar
• Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995;7:1–6.
   PubMed Web of Science ®Google Scholar
• Capri S, Ceci A, Teraanova L, Merlo F, Mantovani LG. Guidelines for economic evaluation in Italy: recommendation from the Italian group of pharmacoeconomic studies. Drug Inform J 2001;35:189–201.
   Web of Science ®Google Scholar
• Lévy E, de Pouvourville G. French Guidelines for The Economic Evaluation of Health Care Technologies - CES-Guidelines - 1997 http://www.ces-asso.org/docs/CES-Guidelines-1997.pdf.
   Google Scholar
• Swiss Federation Office of Social Security. Manual for the Standardization of Clinical and Economic Evaluation of Medical Technology 1998. http://www.ispor.org/peguidelines/countrydet.asp?c=25&t=1
   Google Scholar
• Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C. German recommendations on health economic evaluation: Third and updated version of the Hanover consensus. Value in Health 2008;11(4):534–544.
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Milton Value in Health 2003;6(1):9–17.
   PubMed Web of Science ®Google Scholar
• Ministry Decree 30th June 1997. Tariffe delle prestazioni di assistenza ospedaliera. Gazzetta Ufficiale, n. 209 (suppl); 8 September 1997.
   Google Scholar
• Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003;29(1):29–35.
   PubMed Web of Science ®Google Scholar
• Nebel M: Behandlungskosten der Nierenersatztherapie in Deutsch land 1999. Nieren-und Hochdruckkrankheiten 2002;31:85–92.
   Google Scholar
• Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland – An analysis of the RENAAL study. Swiss Med Wkly 2004;134:440–447.
   PubMed Web of Science ®Google Scholar
• Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian Guidelines in pharmacoeconomics. Pharmacoeconomics 1995;7:1–6.
   PubMed Web of Science ®Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Information Journal 2001;35:189–201.
   Web of Science ®Google Scholar